Systemic methotrexate therapy for psoriasis: Past, present and future

Clinical and Experimental Dermatology

Volumn 38, Issue 6, 2013, Pages 573-588

  Dogra, S ^a   Mahajan, R ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRIAKINUMAB; CYCLOSPORIN; FOLIC ACID; METHOTREXATE; PLACEBO;

ALOPECIA; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN DISEASE; CARDIOTOXICITY; CHILDHOOD DISEASE; CHILL; CLINICAL TRIAL; CYSTITIS; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; ECCHYMOSIS; ERECTILE DYSFUNCTION; FATIGUE; GASTROINTESTINAL TOXICITY; GLOSSITIS; HEMATURIA; HUMAN; HYPERHOMOCYSTEINEMIA; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIBIDO; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MEGALOBLASTIC ANEMIA; MOLLUSCUM CONTAGIOSUM; NAUSEA; NEOPLASM; OLIGOSPERMIA; PHARYNGITIS; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REMISSION; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TERATOGENESIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULCER; UREMIA; URTICARIA; VOMITING;

DERMATOLOGIC AGENTS; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PSORIASIS;

EID: 84880085825     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12062     Document Type: Review

References (115)

1. Farber S, Diamond LK, Mercer RD, et al,. Temporary remissions in acute leukemia in children produced by the folic acid antagonist, 4-aminopteroyl- glutamic acid (aminopterin). New Engl J Med 1948; 238: 787-93.
2. Berlin NI, Rall D, Mead JA, et al,. Folic acid antagonists: effects on the cell and the patient. Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med 1963; 59: 931-56.
3. Gubner R, August S, Ginsberg V,. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 220: 176-82.
4. Belgi G, Friedmann PS,. Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. Clin Exp Dermatol 2001; 27: 546-54.
5. Lebwohl M,. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S59-69.
6. Menter A, Griffiths CEM,. Current and future management of psoriasis. Lancet 2007; 370: 272-84.
7. Chladek K, Martinkova J, Simkova M,. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998; 53: 437-44.
8. Oguey D, Kolliker F, Gerber NJ, Reichen J,. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-14.
9. Grim J, Chladek J, Matinkova J,. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003; 42: 139-51.
10. van Roon EN, van de Laar MA,. Methotrexate bioavailability. Clin Exp Rheumatol 2010; 28: S27-32.
11. Janknegt R, Nube MJ, van den Hoogenband HM, et al,. Pharmacokinetics of methotrexate in continous ambulatory peritoneal dialysis. Pharm Weekbl Sci 1988; 10: 86-9.
12. Castaldo P, Magi S, Nasti AA, et al,. Clinical pharmacogenetics of methotrexate. Curr Drug Metab 2011; 12: 278-86.
13. Assaraf YG,. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006; 9: 227-46.
14. Li WW, Bertino JR,. Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity. Cancer Res 1992; 52: 6866-70.
15. Ranganathan P, Mcleod HL,. Methotrexate pharmacogenetics: the first step towards individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1366-77.
16. Saporito FC, Menter MA,. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004; 50: 301-9.
17. Jeffes EW 3rd, McCullough JL, Pittelkow MR, et al,. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104: 183-8.
18. Heenen M, Laporte M, Noel JC, de Graef C,. Methotrexate induces apoptic cell death in human keratinocytes. Arch Dermatol Res 1998; 290: 240-5.
19. Cronstein BN, Naime D, Osterd E,. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leucocyte accumulation in an in vitro model of inflammation. J Clin Invest 1993; 92: 2675-82.
20. Meephansan J, Ruchusatsawat K, Sindhupak W, et al,. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol 2011; 21: 501-4.
21. El Eishi N, Hegazy R, Abou Zeid O, Shaker O,. Peroxisome proliferator receptor (PPAR)β/δ in psoriatic patients before and after two conventional therapeutic modalities: methotrexate and PUVA. Eur J Dermatol 2011; 21: 691-5.
22. Cronstein B,. How does methotrexate suppress inflammation? Clin Exp Rheumatol 2010; 28: S21-3.
23. Silke C, Murphy MS, Buckley T,. The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology 2001; 40: 34. (abstract).
24. Nesher G, Mates M, Zevin S,. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003; 48: 571-2.
25. Penz Z, Borea PA, Wilder T,. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119: 582-94.
26. Kalb RE, Strober B, Weinstein G, Lebwohl M,. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
27. Benedek TG,. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-α. Clin Exp Rheumatol 2010; 28: S3-8.
28. Weinstein GD, Frost P,. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971; 103: 33-8.
29. Roenigk HH Jr, Maibach HI, Weinstein GD,. Guidelines on methotrexate therapy for psoriasis. Arch Dermatol 1972; 105: 363-5.
30. Pathirana D, Ormerod AD, Saiag P, et al,. European S3: Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: S1-70.
31. Montaudie H, Sbidian E, Paul C, et al,. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors andmonitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25: S12-18.
32. Kumar B, Saraswat A, Kaur I,. Short-term methotrexate therapy in psoriasis: a study of 197 patients. Int J Dermatol 2002; 41: 444-8.
33. Sandhu K, Kumar B, Saraswat A, Kaur I,. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30: 458-63.
34. Mahajan R, Kaur I, Kanwar AJ,. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy in treatment of moderate to severe psoriasis-a randomized placebo controlled study. J Eur Acad Dermatol Venereol 2010; 62, 895-900.
35. Roenigk HH, Auerbach R, Maibach H, et al,. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85.
36. Radmanesh M, Rafiei B, Mossavi ZB, Sina N,. Weekly vs. daily administration of oral methotrexate for generalized plaque psoriasis: a randomized controlled clinical trial. Int J Dermatol 2011; 50: 1291-3.
37. Morgan SL, Oster RA, Lee JY, et al,. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004; 50: 3104-11.
38. Prey S, Paul C,. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160: 622-8.
39. Morgan SL, Baggott JE, Lee JY, Alarcon GS,. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-6.
40. Micha R, Imamura F, Wyler von Ballmoos M, et al,. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70.
41. Dervieux T, Furst D, Lein DO,. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross sectional observational study. Ann Rheum Dis 2005; 64: 1180-5.
42. Chládek J, Simková M, Vanecková J, et al,. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347-55.
43. Visser K, Katchamart W, Loza E,. Multinational evidence-based recommendations for the use of methotrexate in rheumaticdisorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2009; 68: 1086-93.
44. McKendry R,. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997; 23: 939-54.
45. Weinblatt ME, Fraser P,. Elevated meancorpuscular Volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989; 32: 1592-6.
46. Imokawa S, Colby TV, Leslie KO, Helmers RA,. Methotrexate pneumonitis: a review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373-81.
47. Zachariae H,. Methotrexate side-effects. Br J Dermatol 1990; 122: 127-33.
48. Sawada Y, Kawakami C, Nakamura M, et al,. Toxic epidermal necrosis-like dermatosis induced by the first course of methotrexate. Eur J Dermatol 2009; 19: 397-8.
49. Lim KS, Foo CC,. Disseminated molluscum contagiosum in a patient with chronic plaque psoriasis taking methotrexate. Clin Exp Dermatol 2007; 32: 591-8.
50. Kaya TI, Tiftik N, Tursen U, et al,. Ultraviolet recall phenomenon associated with methotrexate and cytarabine. J Eur Acad Dermatol Venereol 2006; 20: 341-62.
51. Chalmers RJG, Kirby B, Smith A, et al,. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005; 152: 444-50.
52. Barbero-Villares A, Mendoza J, Trapero-Marugan M, et al,. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011; 26: 637-9.
53. Abenavoli L, Beaugrand M,. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol 2012; 11: 172-8.
54. ™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
55. Bray AP, Barnova I, Przemioslo R, Kennedy CT,. Liver fibrosis screening for patients with psoriasis taking methotrexate: a crosssectional study comparing transient elastography and liver biopsy. Br J Dermatol 2012; 166: 1125-7.
56. Wylie G, Evans CD, Gupta G,. Reduced libido and erectile dysfunction: rarely reported side-effects of methotrexate. Clin Exp Dermatol 2009; 34: e234.
57. Hoeltzenbein M, Weber-Schondorfer C, von Stackelberg L, Schaefer C,. Paternal exposure to drugs-is there an increased risk for congenital abnormalities? Experience of the Berlin Institute of Clinical Teratology and Drug Risk Assessment during Pregnancy. Reprod Toxicol 2008; 26: 64 (abstract).
58. Østensen M, von Esebeck M, Villiger PM,. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 2007; 34: 1266-9.
59. Handa S, Saraswat A, Kaur I, Kumar B,. Excessive drowsiness with low-dose methotrexate. Int J Dermatol 2004; 43: 701-2.
60. Greenblatt D, Sheth N, Teixeira F, Acland K,. Isolated sixth nerve palsy following low dose oral methotrexate. Dermatol Online J 2007; 13: 19.
61. Clare G, Colley S, Kennett R, Elston JS,. Reversible optic neuropathy associated with low dose methotrexate therapy. J Neuroopthalmol 2005; 25: 109-12.
62. Zargari O,. Methotrexate, hyperosmia and migraine. Dermatol Online J 2006; 12: 28.
63. Martínez-Raposo Piedrafita MC, Esteban Jiménez O, Baile Estopañán G, Navarro Pemán C,. Encephalopathy secondary to methotrexate. Med Clin (Barc) 2010; 134: 662-3.
64. Balbir-Gurman A, Guralnik L, Best LA, et al,. Accelerated pulmonary nodulosis and sterile pleural effusion in a patient with psoriatic arthropathy during methotrexate therapy: a case report. J Clin Rheumatol 2009; 15: 29-30.
65. Bologna C, Sany J, Jorgensen C,. Possible role of methotrexate in the distal tibia fractures in a patient with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 343-4.
66. Rozin AP,. Is methotrexate osteopathy a form of bone idiosyncrasy? Ann Rheum Dis 2003; 62: 1123.
67. Alonso-Bartolome P, Martinez-Taboada VM, Canga A, Blanco R,. Medial tibial stress syndrome due to methotrexate osteopathy. Ann Rheum Dis 2006; 65: 832-3.
68. Kanik KS, Cash JM,. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997; 23: 955-67.
69. Jensen DB, Albrektsen SB, Krag C,. Development of metastatic skin cancer during methotrexate therapy for psoriasis. Acta Derm Venereol 1989; 69: 274-5.
70. Bailin PL, Tindall JP, Roenigk HH Jr, Horgen MD,. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective prospective analysis. JAMA 1975; 23: 2359-62.
71. Stern RS, Zierler S, Parrish JA,. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982; 50: 869-72.
72. Nysfors A, Jensen H,. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study. Dermatologica 1983; 167: 260-1.
73. Marcil I, Stern RS,. Squamous-cell cancer of the skin in patients given PUVA and ciclosporine: nested cohort crossover study. Lancet 2001; 358: 1042-5.
74. Buchbinder R, Barber M, Heuzenroeder L, et al,. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008; 59: 794-9.
75. Strangfeld A, Hierse F, Rau R, et al,. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12: R5.
76. Persad P, Levender MM, Feldman SR,. Commentary: psoriasis patients with a history of malignancy represent an important but overlooked study population. Dermatol Online J 2011; 17: 10.
77. Schewash-Millet M, Ziprkowski L,. Methotrexate in psoriasis. Br J Dermatol 1968; 80: 534-9.
78. Baker H,. Intermittent high dose oral methotrexate therapy in psoriasis. Br J Dermatol 1970; 82: 65-9.
79. Collins P, Rogers S,. The efficacy of methotrexate in psoriasis-a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60.
80. van Dooren-Greebe RJ, Kuipers AL, Mulder J, et al,. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10.
81. van Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, van de Kerkhof PC,. Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995; 75: 393-6.
82. Haustein UF, Rytter M,. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Euro Acad Dermatol Venereol 2000; 14: 382-8.
83. Hyedendael VM, Spuls PI, Opmeer BC, et al,. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65.
84. Ranjan N, Sharma NL, Shanker V, et al,. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J Dermatolog Treat 2007; 18: 295-300.
85. Flytstrom I, Stenberg B, Svensson A, Bergbrant IM,. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-21.
86. Saurat JH, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
87. Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S,. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2010; 24: 1447-51.
88. Reich K, Signorovich J, Ramakrishnan K, et al,. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis. Comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 2010; 63: 1011-18.
89. Ho SG, Yeung CK, Chan HH,. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life. Clin Exp Dermatol 2010; 35: 717-22.
90. Fallah Arani S, Neumann H, Hop WC, Thio HB,. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol 2011; 164: 855-61.
91. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab versus methotrexate in patients with moderate-to-severe plaque psoriasis. Results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
92. Reich K, Langley RG, Papp KA, et al,. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365: 1586-96.
93. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB,. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 6: 46-51.
94. Paul BS, Momtaz K, Stern RS, et al,. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7: 758-62.
95. Clark CM, Kirby B, Morris AD, et al,. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279-82.
96. de Jong EM, Mork NJ, Seijger MM, et al,. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003; 148: 318-25.
97. Shehzad T, Dar NR, Zakria M,. Efficacy of concomitant use of PUVA and methotrexate in disease clearance time in plaque type psoriasis. J Pak Med Assoc 2004; 54: 453-5.
98. Fraser AD, van Kuijk AW, Westhovens R, et al,. A randomised, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64: 859-64.
99. Asawanonda P, Nateetongrungsak Y,. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006; 54: 1013-18.
100. Aydin F, Canturk T, Senturk N, Turanli AY,. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006; 31: 520-4.
101. Lowenthal KE, Horn PJ, Kalb RE,. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008; 19: 22-6.
102. Mease PJ, Gladman DD, Keystone EC,; Alefacept in PsA Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1638-45.
103. Zachariae C, Mørk NJ, Reunala T, et al,. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88: 495-501.
104. Yamauchi PS, Lowe NJ,. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Int J Dermatol 2008; 47: 202-4.
105. Driessen RJ, van de Kerkhof PC, de Jong EM,. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol 2008; 159: 460-3.
106. Mease PJ, Reich K,. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009; 60: 402-11.
107. Gottlieb AB, Langley RG, Strober BE, et al,. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012; 167: 649-57.
108. Staidle JP, Dabade TS, Feldman SR,. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011; 12: 2041-54.
109. Morgaceva O, Furst DE,. Use of MTX in the elderly and in patients with compromised renal function. Clin Exp Rheumatol 2010; 28: S85-94.
110. Kumar B, Dhar S, Handa S, Kaur I,. Methotrexate in childhood psoriasis. Pediatr Dermatol 1994; 11: 271-3.
111. Dogra S, Kumaran MS, Handa S, Kanwar AJ,. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol 2005; 22: 85-6.
112. Kaur I, De Dogra SD, Kanwar AJ,. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol 2008; 25: 184-8.
113. Collin B, Vani A, Ogboli M, Moss C,. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol 2009; 34: 295-8.
114. Heldman F, Brown J,. Perioperative use of methotrexate. Clin Exp Rheumatol 2010; 28: S110-13.
115. Castaneda O, Nair MG,. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis. J Rheumatol 2006; 33: 862-4.